全球癌症基因治療市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

預計癌症基因治療市場將從 2025 年的 61.6 億美元成長到 2034 年的 298.6 億美元，2026 年至 2034 年的複合年成長率為 19.17%。

受分子生物學和基因工程領域進步的推動，全球癌症基因治療市場正經歷快速成長。全球癌症發生率的不斷攀升加速了創新治療方法的研究。基因治療透過糾正或替換缺陷基因，提供標靶治療方案，從而提高治療的精準度。對腫瘤學研究和臨床試驗投入的增加，也大大促進了市場的發展。

關鍵成長要素包括病毒載體技術和基於CRISPR的基因編輯工具的突破性進展。個人化醫療的日益普及正在推動對基因治療方法的需求。新型基因療法的監管核准將進一步促進創新。此外，生技公司與研究機構之間的合作正在加速產品商業化和市場擴張。

展望未來，隨著遞送系統和安全性方面的不斷進步，市場預計將持續成長。公眾意識的提高和報銷機制的完善將加速其普及。新興市場不斷完善的癌症治療基礎設施也帶來了新的機會。隨著基因編輯技術的研究不斷進步，癌症基因療法有望成為癌症治療領域的變革性力量。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球癌症基因治療市場：依治療方法

• 市場分析、洞察與預測
• 溶瘤病毒療法
• 基因誘導免疫療法
• 基因轉移

第5章：全球癌症基因治療市場：依最終用途分類

• 市場分析、洞察與預測
• 研究機構
• 生物製藥公司
• 診斷中心
• 其他

第6章 全球癌症基因治療市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第7章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第8章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Abeona Therapeutics Inc
  • Asklepios BioPharmaceutical Inc
  • Altor Bioscience Corp
  • Bluebird Bio Inc
  • BioCancell Therapeutics Inc
  • Celgene Corporation
  • Elevate Bio Inc
  • GlaxoSmithKline Plc
  • Genelux Corporation
  • GenVec Inc
  • Introgen Therapeutics Inc
  • Merck KGaA
  • OncoGenex Pharmaceuticals Inc

The Cancer Gene Therapy Market size is expected to reach USD 29.86 Billion in 2034 from USD 6.16 Billion (2025) growing at a CAGR of 19.17% during 2026-2034.

The Global Cancer Gene Therapy Market is witnessing rapid growth due to advancements in molecular biology and genetic engineering. Increasing prevalence of cancer worldwide has accelerated research in innovative treatment approaches. Gene therapy offers targeted solutions by modifying or replacing defective genes, improving treatment precision. Rising investments in oncology research and clinical trials are significantly supporting market development.

Key growth drivers include breakthroughs in viral vector technology and CRISPR-based gene editing tools. Expanding adoption of personalized medicine enhances the demand for gene-based therapies. Regulatory approvals of novel gene therapies encourage further innovation. Additionally, collaborations between biotechnology firms and research institutions accelerate product commercialization and market expansion.

Looking ahead, the market is expected to grow with ongoing advancements in delivery systems and safety profiles. Increased awareness and improved reimbursement frameworks will facilitate adoption. Emerging markets with expanding oncology infrastructure present new opportunities. As research continues to refine gene-editing technologies, cancer gene therapy is poised to become a transformative force in oncology treatment.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product Therapy

• Oncolytic Virotherapy
• Gene Induced Immunotherapy
• Gene Transfer

By End Use

• Research Institutes
• Biopharmaceutical Companies
• Diagnostic Centers
• Others

COMPANIES PROFILED

• Abeona Therapeutics Inc, Asklepios BioPharmaceutical Inc, Altor Bioscience Corp, Bluebird Bio Inc, BioCancell Therapeutics Inc, Celgene Corporation, Elevate Bio Inc, GlaxoSmithKline plc, Genelux Corporation, GenVec Inc, Introgen Therapeutics Inc, Merck KGaA, OncoGenex Pharmaceuticals Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CANCER GENE THERAPY MARKET: BY PRODUCT THERAPY 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product Therapy
• 4.2. Oncolytic Virotherapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Gene Induced Immunotherapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Gene Transfer Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CANCER GENE THERAPY MARKET: BY END USE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast End Use
• 5.2. Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Biopharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Diagnostic Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CANCER GENE THERAPY MARKET: BY REGION 2022-2034(USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Product Therapy
  • 6.2.2 By End Use
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Product Therapy
  • 6.3.2 By End Use
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Product Therapy
  • 6.4.2 By End Use
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Product Therapy
  • 6.5.2 By End Use
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 South East Asia
  • 6.5.8 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Product Therapy
  • 6.6.2 By End Use
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL CANCER GENE THERAPY INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 Abeona Therapeutics Inc
  • 8.2.2 Asklepios BioPharmaceutical Inc
  • 8.2.3 Altor Bioscience Corp
  • 8.2.4 Bluebird Bio Inc
  • 8.2.5 BioCancell Therapeutics Inc
  • 8.2.6 Celgene Corporation
  • 8.2.7 Elevate Bio Inc
  • 8.2.8 GlaxoSmithKline Plc
  • 8.2.9 Genelux Corporation
  • 8.2.10 GenVec Inc
  • 8.2.11 Introgen Therapeutics Inc
  • 8.2.12 Merck KGaA
  • 8.2.13 OncoGenex Pharmaceuticals Inc